NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $21.63 -0.85 (-3.78%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$21.41 -0.22 (-1.02%) As of 08/14/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amylyx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$21.29▼$22.3950-Day Range$13.01▼$24.1952-Week Range$7.63▼$24.60Volume1.59 million shsAverage Volume2.02 million shsMarket Capitalization$2.41 billionP/E RatioN/ADividend YieldN/APrice Target$25.38Consensus RatingModerate Buy Company Overview Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options. The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S. Food and Drug Administration approval in 2022 for the treatment of amyotrophic lateral sclerosis (ALS). Amylyx has also filed for regulatory approval of AMX0035 (known as Albrioza) in the European Union and continues to explore its potential utility in other neurodegenerative disorders. In addition to ALS, the Amylyx pipeline includes early-stage programs investigating therapies for Alzheimer’s disease and GM1 gangliosidosis, reflecting the company’s broader commitment to addressing central nervous system pathologies. Amylyx operates primarily in North America and is advancing its global development and commercialization capabilities through strategic collaborations and regulatory engagements. Under the leadership of Chief Executive Officer John H. Johnson III, the company continues to expand clinical development efforts and strengthen its manufacturing and distribution networks. Amylyx’s multidisciplinary team of scientists, clinicians and regulatory experts works to translate preclinical discoveries into potential therapies for patients facing critical neurological challenges.AI Generated. May Contain Errors. Read More Amylyx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreAMLX MarketRank™: Amylyx Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 516th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAmylyx Pharmaceuticals has a consensus price target of $25.38, representing about 17.3% upside from its current price of $21.63.Amount of Analyst CoverageAmylyx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($1.45) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -15.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -15.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 10.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.50% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 6.84.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 9.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth.Read more about Amylyx Pharmaceuticals' dividend. News and Social Media2.6 / 5News Sentiment0.13 News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $274,800.00 in company stock.Percentage Held by Insiders10.90% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMLX Stock News HeadlinesAmylyx Pharmaceuticals (AMLX) Is Down 7.1% After Wider Q2 Loss And Avexitide Phase III UpdateAugust 14 at 12:16 PM | finance.yahoo.comAmylyx (AMLX) Q2 2026 Earnings Call TranscriptAugust 13 at 3:32 PM | finance.yahoo.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.August 16 at 1:00 AM | Profits Run (Ad)Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 13 at 2:46 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for AMLX Q3 Earnings?August 13 at 1:58 AM | americanbankingnews.comFY2029 Earnings Estimate for AMLX Issued By HC WainwrightAugust 10, 2026 | americanbankingnews.comAmylyx Pharmaceuticals: Avexitide Defines The Endocrine RebuildAugust 7, 2026 | seekingalpha.comAmylyx anticipates Phase III LUCIDITY top-line data in late August or early September with $250.8M cash runway into 2028August 7, 2026 | seekingalpha.comSee More Headlines AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $12.08 at the beginning of the year. Since then, AMLX stock has increased by 79.1% and is now trading at $21.63. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) posted its earnings results on Thursday, August, 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.03. Read the conference call transcript. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Thursday, January 6th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' top institutional investors include BlackRock Inc. (7.94%), Jupiter Topco LLC (4.70%), Connor Clark & Lunn Investment Management Ltd. (0.65%) and Deutsche Bank AG (0.50%). Insiders that own company stock include Joshua B Cohen, Justin B Klee, George M Milne Jr, Patrick D Yeramian, Gina Mazzariello, James M Frates, Camille L Bedrosian, Karen Firestone, Bernhardt G Zeiher and Daphne Quimi. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amylyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/06/2026Today8/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 AMLX's financial health is in the Green zone, according to TradeSmith. AMLX has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AMLX CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees200Year Founded2013Price Target and Rating Average Price Target for Amylyx Pharmaceuticals$25.38 High Price Target$40.00 Low Price Target$19.00 Potential Upside/Downside+17.3%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$144.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.92% Return on Assets-48.53% Debt Debt-to-Equity RatioN/A Current Ratio12.12 Quick Ratio12.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.15 per share Price / Book10.06Miscellaneous Outstanding Shares111,423,000Free Float99,278,000Market Cap$2.41 billion OptionableOptionable Beta-0.21 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:AMLX) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
